HAMBURG, Germany, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN: DE0005664809) today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.
Help employers find you! Check out all the jobs and post your resume.
